Delcath Systems, Inc. Delcath Systems, Inc.

Delcath Systems, Inc.

DCTH

Rank in Stocks #10124
Delcath Systems, Inc. is an interventional oncology firm operating in the... Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
Share Price
$19.37
Last synced: 2026-11-17
Market Cap
$698.76M
Change (1 day)
-2.52%
Change (1 year)
116.18%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
EPS for Delcath Systems, Inc. (DCTH)
EPS as of September 2026 TTM: $0.18
According to Delcath Systems, Inc.'s latest financial reports, its current EPS (TTM) is $0.18. At the end of 2025 the company had an EPS of $0.08, an increase over its 2024 EPS of $-0.11.
EPS history for Delcath Systems, Inc. from 2000 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $0.18 125.00%
2025 $0.08 -175.47%
2024 $-0.11 -78.14%
2023 $-0.49 -88.22%
2022 $-4.12 14.74%
2021 $-3.59 -57.04%
2020 $-8.36 -97.56%
2019 $-342.82 -99.93%
2018 $-503.85K -99.98%
2017 $-2.28B -99.50%
2016 $-452.62B -1.07%
2015 $-457.51B -23.64%
2014 $-599.15B -51.63%
2013 $-1.239T -95.33%
2012 $-26.546T 166.35%
2011 $-9.966T -73.46%
2010 $-37.547T 552.88%
2009 $-5.751T 85.26%
2008 $-3.104T -39.69%
2007 $-5.147T -3.50%
2006 $-5.334T 328.96%
2005 $-1.243T -41.84%
2004 $-2.138T 26.68%
2003 $-1.688T -87.84%
2002 $-13.872T 197.42%
2001 $-4.664T -74.88%
2000 $-18.568T 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$2.70 1,400.00%
US
$4.09 2,172.22%
IE
$9.45 5,150.00%
US
$2.37 1,216.67%
US
$1.77 883.33%
US

Questions about Delcath Systems, Inc.'s earnings per share (EPS)

What is Delcath Systems, Inc.'s earnings per share (EPS)?

Delcath Systems, Inc.'s earnings per share (EPS) over the last twelve months is $0.18, as of Sep 2026.

What was Delcath Systems, Inc.'s earnings per share (EPS) in 2025?

In 2025, Delcath Systems, Inc.'s earnings per share (EPS) was $0.08, compared with $-0.11 in 2024.

How has Delcath Systems, Inc.'s earnings per share (EPS) changed since 2020?

From 2020 to 2025, Delcath Systems, Inc.'s earnings per share (EPS) was highest in 2025 ($0.08) and lowest in 2020 ($-8.36).

How does Delcath Systems, Inc.'s earnings per share (EPS) compare with similar companies?

Delcath Systems, Inc.'s earnings per share (EPS) ($0.18) is lower than that of all 5 similar companies listed above. The highest among them is Stryker Corporation, with $9.45.